Sant Kumar

@CreightonPhxCVD via @gtown_medres and @GUMedicine

[EuroIntervention @EuroInterventio]

Intravascular imaging-guided PCI was associated with a significantly lower risk of target vessel failure compared with angiography-guided PCI across all levels of lesion complexity, with increasing prognostic benefit in more complex disease.
Pooled analysis of 4,611 patients from RENOVATE-COMPLEX PCI and registry data.
#EIJBestOf #PCI #IntravascularImaging #InterventionalCardiology

🔗https://t.co/cHU1S5xYsx

[EuroIntervention @EuroInterventio]

New issue now online!
✅P2Y12 inhibitor monotherapy after complex PCI; ✅Ticagrelor monotherapy in STEMI;
✅Endotype-based treatment in ANOCA;
✅Vasomotor dysfunction after PCI;
✅Collapse of a new-generation magnesium scaffold; and more
https://t.co/B3NtvqPM3L

@sbrugaletta @CaiaCrooijmans @teresabastante
@RoccoMontone @valeriaparadies @Giando611 @piccoloraf @antoniop_vitale

[American College of Cardiology @ACCinTouch]

Lower BMI in older pts undergoing #TAVR was associated w/ ⬆️ risk of all-cause mortality & major CV & cerebrovascular events at one year; however, outcomes did not differ between BMI groups among pts younger than 65 years old. 🔗 https://t.co/O2wPs37jqK #JACCAdvances #NCDR

[Sant Kumar @Sant_J_Kumar]

🎯 The key message: technical feasibility does not equal clinical safety.

Patients undergoing ViMAC TMVR are often highly comorbid and anatomically complex at baseline, which may contribute to the substantial early hazard. BATMAN 🦇 should therefore be reserved for carefully selected patients after:

👥 Multidisciplinary review
💬 Shared decision-making
⚖️ Careful assessment of anticipated benefit versus procedural risk

https://t.co/KbGPPDoIx7
@JACCJournals #JACCCaseReports

@engelpedro @GKFram @Brianponeill @Tiberio_Frisoli @PedroMDMSc

[Sant Kumar @Sant_J_Kumar]

🦇🫀 Is BATMAN-facilitated native valve-in-MAC TMVR technically feasible in patients with complex anatomy and high predicted LVOT obstruction risk?

In our newly published case series, 11 highly symptomatic patients underwent balloon-assisted translocation of the anterior mitral leaflet before TMVR. Key findings 🧵👇 @ArturoGiacaman @PedroMDMSc @JACCJournals #JACCCaseReports

[Sant Kumar @Sant_J_Kumar]

📉 Immediate hemodynamics were encouraging:

🫀 Predischarge transmitral gradient: 5.4 ± 1.7 mm Hg

However, early risk remained substantial:
⚠️ PVL requiring closure: 27%
🏥 In-hospital mortality: 18%
📅 30-day mortality: 36%—2 cardiac and 2 noncardiac deaths

[NEJM @NEJM]

Among patients with multivessel coronary artery disease who were in stable condition 1 year after stenting, an additional year of DAPT led to a lower risk of ischemic events than aspirin alone, without increased bleeding. Full DAPT-MVD trial results: https://t.co/iHRM4Gv3ND

Editorial: Balancing the Scales — Extended DAPT in Coronary Artery Disease https://t.co/Nxqwkd4Trr

[EuroIntervention @EuroInterventio]

From coronary physiology and PCI timing to coronary re-access and coronary obstruction prevention, this State-of-the-Art review provides practical guidance for managing coronary interventions in patients undergoing TAVI. 🔗https://t.co/SjF9384oBS #TAVI #CoronaryInterventions #StructuralHeartDisease

@GilbertTangMD

@didier_tchetche

@barbanti_marco
@AnderRegueiro
@nicolo_piazza
@G_Tarantini01

[Sant Kumar @Sant_J_Kumar]

@georgetolisjr Respectfully, success requires the ability to identify why failure occurred, address those issues, and persevere. Quitting when one fails should not be the attribute we aim for, in medicine or anything else.

[JACC Journals @JACCJournals]

BATMAN was associated with high technical success and effectiveness in preventing #LVOT obstruction and appeared to be safe in ViR and ViV procedures. Adverse events were higher in ViMAC. https://t.co/GooSIkbKxz #JACCINT #TMVR

[Asaad Nakhle, MD @asaadnakhle]

An overhanging stent is difficult to deal with. Here’s a solution: Remove it and start fresh. This is one of few cases we’ve done at Henry Ford Hospital. All successful, no adverse events.

https://t.co/vE52ne5S91

@HenryFordHealth @hfhcardiofellow @JACCJournals @KAlaswadMD

[FRANCESCO BURZOTTA @BURZOTTA_F]

After 2 years of work, the 🇪🇺 consensus on #IVUS  #OCT use in #LM #PCI is now published in #EHJ. Great international  collaboration coordinated by #EBC and #EAPCI !!!
It includes fantastic practical images that can be hung on the walls of all cath labs…
https://t.co/2TbBTIoMxu

[Alfonso Jurado-Román @JuradoRomanAl]

KUDOS to @CamachoFreire @AntonioGomezM21 and all the team for such an important study. Amazing job that fills the GAP of #OCT threshold to treat or defer #LM treatment. Very happy to collaborate from @Hemodin_LaPaz with our friends of @hujuanramon 👏🏾👏🏾👏🏾👏🏾 @shci_sec @PCRonline

[CircInterventions @CircIntv]

Does the clinical benefit of intravascular imaging-guided PCI differ between focal & diffuse CAD? A LBCT presented at #EuroPCR & published simultaneously @ColinBerryMD @wfearonmd @divaka_perera @fer_iver @juliendjdj @SimoneBiscaglia @DrAllenJ @DMunhoz https://t.co/eJs2q7IxHG

[PCRonline 🫀 @PCRonline]

🔥 #EuroPCR 2026 Major Late-Breaking Trials: Long-term mortality following PCI with DES versus CABG for left main disease

An individual participant data meta-analysis of the SYNTAX, PRECOMBAT, NOBLE and EXCEL trials presented by Brian Bergmark showed no significant difference in all-cause mortality between DES PCI and CABG over 10-year follow-up in patients with left main coronary artery disease suitable for revascularisation.

Read the press release here: https://t.co/IWwgQBtbbU

@NievesGonzalo1 @CuissetDr @nicolasdumonte1

#LeftMain #PCI #CABG #CoronaryArteryDisease #InterventionalCardiology #ClinicalTrials

[Sant Kumar @Sant_J_Kumar]

@hrt01a @DrHurshNaik

[Ryo Horita, MD. @hrt01a]

TriClip has come to Hokkaido!

We performed three #TriClip cases, including the first case at our hospital.
All three cases improved from massive TR to mild TR.
We will keep working to advance TR treatment in Hokkaido and Japan !
Special thanks to Dr. Naik for the great support.

[REC Publications @RevEspCardiol]

An interview with Lorenzo Azzalini #recintervcardiol #Aheadofprint @OjedaOjeda18 @LAzzaliniMD https://t.co/SLMlWI6sgO

[Evandro Martins F. MD @evandrofilhobr]

1/16 🧵 ORBITA-CTO: The first randomized, placebo-controlled trial of CTO PCI.

📰 Published in JACC, presented at #ACC26.

🔬 Finally, sham-controlled evidence for what we do in the cath lab every day.

One of the best designed studies I have ever seen!

A biostatistical deep dive. Let's go. 👇